Recent advances in microfluidic technology and applications for anti-cancer drug screening

2020 ◽  
pp. 116118
Author(s):  
Yiwei Shi ◽  
Ying Cai ◽  
Yuhong Cao ◽  
Zhanying Hong ◽  
Yifeng Chai
Keyword(s):  
Drug Screening ◽  
Cancer Drug ◽  
Recent Advances ◽  
Microfluidic Technology ◽  
Anti Cancer

scholarly journals Anti-Cancer Drug Screening with Microfluidic Technology

2021 ◽  
Vol 11 (20) ◽  
pp. 9418
Author(s):  
Mojdeh Monjezi ◽  
Milad Rismanian ◽  
Hamidreza Jamaati ◽  
Navid Kashaninejad
Keyword(s):  
Drug Screening ◽  
Animal Studies ◽  
Ethical Issues ◽  
Cancer Drug ◽  
Screening Methods ◽  
Microfluidic Chips ◽  
Microfluidic Systems ◽  
Microfluidic Technology ◽  
Anti Cancer ◽  
Clinical Experiments

The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in microfluidic systems has many advantages. For instance, these platforms offer high-throughput drug screening, require a small number of samples, provide an in vivo-like microenvironment for cells, and eliminate ethical issues associated with animal studies. Multiple cell cultures in microfluidic chips could better mimic the 3D tumor environment using low reagents consumption. The clinical experiments have shown that combinatorial drug treatments have a better therapeutic effect than monodrug therapy. Many attempts have been made in this field in the last decade. This review highlights the applications of microfluidic chips in anti-cancer drug screening and systematically categorizes these systems as a function of sample size and combination of drug screening. Finally, it provides a perspective on the future of the clinical applications of microfluidic systems for anti-cancer drug development.

scholarly journals Anti-Cancer Drug Screening with Microfluidic Technology

2021 ◽  
Author(s):  
Mojdeh Monjezi ◽  
Milad Rismanian ◽  
Hamidreza Jamaati ◽  
Navid Kashaninejad
Keyword(s):  
Drug Screening ◽  
Animal Studies ◽  
Ethical Issues ◽  
Cancer Drug ◽  
Screening Methods ◽  
Microfluidic Chips ◽  
Microfluidic Systems ◽  
Microfluidic Technology ◽  
Anti Cancer ◽  
Clinical Experiments

The up-and-coming microfluidic technology is the most promising platform for designing anti-cancer drugs and new point-of-care diagnostics. Compared to conventional drug screening methods based on Petri dishes and animal studies, drug delivery in microfluidic systems has many advantages. For instance, these platforms offer high throughput drug screening, require a small amount of samples, provide an in vivo-like microenvironment for cells, and eliminate ethical issues associated with animal studies. Multiple cell cultures in microfluidic chips could better mimic the 3D tumor environment using low reagents consumption. The clinical experiments have shown that combinatorial drug treatments have a better therapeutic effect than monodrug therapy. So many attempts were performed in this field in the last decade. This review highlights the applications of microfluidic chips in anti-cancer drug screening and systematically categorizes these systems as a function of sample size and combination of drug screening. Finally, it provides a perspective on the future of the clinical applications of microfluidic systems for anti-cancer drug development.

Cell sheet-based multilayered liver tumor models for anti-cancer drug screening

2017 ◽  
Vol 40 (2) ◽  
pp. 427-435 ◽  
Author(s):  
Jianing Yang ◽  
Shengjun Zhao ◽  
Yunfei Ji ◽  
Lili Zhao ◽  
Qingzhu Kong ◽  
...  
Keyword(s):  
Drug Screening ◽  
Liver Tumor ◽  
Cell Sheet ◽  
Cancer Drug ◽  
Tumor Models ◽  
Anti Cancer

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4879-4879
Author(s):  
Myoung Woo Lee ◽  
Hye Jin Kim ◽  
Dae Seong Kim ◽  
Meong Hi Son ◽  
Soo Hyun Lee ◽  
...  
Keyword(s):  
Animal Model ◽  
Mouse Model ◽  
Drug Screening ◽  
Scid Mouse ◽  
Lymphoblastic Leukemia ◽  
Cancer Drug ◽  
Screening System ◽  
Bioluminescent Signal ◽  
Anti Cancer

Abstract Abstract 4879 Background. A hematological malignant animal model is an essential tool for evaluating efficacy of anti-cancer drugs and elucidating underlying mechanism of leukemogenesis. Intraperitoneal (IP) and intravenous (IV) xenograft of acute lymphoblastic leukemia (ALL) cells have limited capacity as in vivo anti-cancer drug screening system. Purpose. In this study, we aimed to establish an ALL animal model using NOD/SCID mouse and evaluate efficiency and sensitivity of the model as a preclinical drug screening system. Materials and Methods. Firefly luciferase (fLuc)-gene introduced ALL (ALL/fLuc) cell line and patient-originated ALL cells were transplanted into a tibia of NOD/SCID mouse. We conducted a comparative analysis of intra-bone marrow (IBMT) transplanted leukemia model with IP and IV transplantation of leukemic cells. Results. IBMT of ALL/fLuc cells effectively established a bioluminescent leukemia NOD/SCID mouse model. Upon comparison of IBMT model with IP and IV transplantation models, infusing identical number of ALL/fLuc cells into NOD/SCID mice resulted in IBMT model with evaluable bioluminescent signal, but not in IP and IV models. In IBMT model, bioluminescent signals of ALL/fLuc cells emitted from peripheral blood, tibia and infiltrated organs indicated that leukemia model was established. The changes in these signals' strength reflected dose-dependent cytotoxic effects of vincristine, which allowed leukemia model with evaluable bioluminescent signal to be utilized as a preclinical drug screening system. IBMT leukemia model was also established using primary ALL cells that can provide additional insights for the development of leukemia therapeutics. Conclusion. IBMT of ALL/fLuc cells enables development of leukemia mouse model with the greater bioluminescent sensitivity than IP and IV in NOD/SCID to evaluate candidate for development of anti-cancer drug. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Validation of a novel perfusion bioreactor system in cancer research

2020 ◽  
Vol 74 (3) ◽  
pp. 187-196
Author(s):  
Jasmina Stojkovska ◽  
Jovana Zvicer ◽  
Milena Milivojevic ◽  
Isidora Petrovic ◽  
Milena Stevanovic ◽  
...  
Keyword(s):  
Cancer Research ◽  
Drug Screening ◽  
Cancer Drug ◽  
Perfusion Bioreactor ◽  
Animal Testing ◽  
Anti Cancer ◽  
Medium Flow ◽  
Bioreactor System

Development of drugs is a complex, time- and cost-consuming process due to the lack of standardized and reliable characterization techniques and models. Traditionally, drug screening is based on in vitro analysis using two-dimensional (2D) cell cultures followed by in vivo animal testing. Unfortunately, application of the obtained results to humans in about 90 % of cases fails. Therefore, it is important to develop and improve cell-based systems that can mimic the in vivo-like conditions to provide more reliable results. In this paper, we present development and validation of a novel, user-friendly perfusion bioreactor system for single use aimed for cancer research, drug screening, anti-cancer drug response studies, biomaterial characterization, and tissue engineering. Simple design of the perfusion bioreactor provides direct medium flow at physiological velocities (100?250 ?m s-1) through samples of different sizes and shapes. Biocompatibility of the bioreactor was confirmed in short term cultivation studies of cervical carcinoma SiHa cells immobilized in alginate microfibers under continuous medium flow. The results have shown preserved cell viability indicating that the perfusion bioreactor in conjunction with alginate hydrogels as cell carriers could be potentially used as a tool for controlled anti-cancer drug screening in a 3D environment.

scholarly journals Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system

PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0215080 ◽  
Author(s):  
Jang Ho Cho ◽  
Ju-Sun Kim ◽  
Seung Tae Kim ◽  
Jung Yong Hong ◽  
Joon Oh Park ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Cell Lines ◽  
Drug Screening ◽  
Cancer Drug ◽  
Screening System ◽  
Tumor Cell Lines ◽  
Area Method ◽  
Anti Cancer ◽  
Colony Area
Sign in / Sign up

Export Citation Format

Share Document